Losmapimod
Losmapimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against mitogen-activated protein kinase 14.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acute coronary syndrome | D054058 | EFO_0005672 | 2 | 1 | 1 | — | — | 4 | |
Facioscapulohumeral muscular dystrophy | D020391 | EFO_0000491 | G71.02 | — | 3 | 1 | — | — | 4 |
Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | 5 | — | — | — | 7 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 2 | 1 | — | — | — | 3 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 2 | — | — | — | 3 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | — | — | — | 2 |
Healthy volunteers/patients | — | 1 | 1 | — | — | — | 2 | ||
Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 | |
Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | 1 | — | — | — | 1 | |
Dyslipidemias | D050171 | HP_0003119 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LOSMAPIMOD |
INN | losmapimod |
Description | 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide is a phenylpyridine. |
Classification | Small molecule |
Drug class | immunomodulators: mitogen-activated protein (MAP) kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1 |
Identifiers
PDB | — |
CAS-ID | 585543-15-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1088752 |
ChEBI ID | — |
PubChem CID | 11552706 |
DrugBank | DB12270 |
UNII ID | F2DQF16BXE (ChemIDplus, GSRS) |
Target
Agency Approved
MAPK14
MAPK14
Organism
Homo sapiens
Gene name
MAPK14
Gene synonyms
CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A
NCBI Gene ID
Protein name
mitogen-activated protein kinase 14
Protein synonyms
CSAID-binding protein, CSBP, cytokine suppressive anti-inflammatory drug binding protein, Cytokine suppressive anti-inflammatory drug-binding protein, MAP kinase 14, MAP kinase MXI2, MAP kinase p38 alpha, MAX-interacting protein 2, Mitogen-activated protein kinase p38 alpha, p38 MAP kinase, p38 mitogen activated protein kinase, p38alpha Exip, SAPK2a, Stress-activated protein kinase 2a
Uniprot ID
Mouse ortholog
Mapk14 (26416)
mitogen-activated protein kinase 14 (P47811)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 400 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,745 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more